GGrantIndex
← Leaderboards

Kathryn Margaret Edwards

Vanderbilt University

$34,281,287
Attributed
$34,281,287
Total exposure
31
Grants
24
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $8.9M · FY200521
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21

Funding mix

By agency

NIH$27,113,662 · 28
CDC$7,167,625 · 3

By mechanism

N01$25,307,714 · 3
U18$3,605,606 · 2
U01$3,562,019 · 1
M01$1,682,784 · 24
T32$123,164 · 1

Top collaborators

No co-investigators on record.

Most similar at Vanderbilt University

Same institution · by research overlap

Others in their field

Top investigators on “Resources

Research focus

ResourcesVaccinesEvaluationConduct Clinical TrialsContractsDesignInfectious Disease TreatmentRouteInvestigationNamed GroupClinical TrialsVaccine CandidateSourceUnited States National Institutes Of HealthInstitutionComputer Retrieval Of Information On Scientific Projects DatabaseFundingGrantResearch PersonnelClinical ResearchHuman SubjectInfluenza Virus VaccineChildhoodInfluenza A Virus, H5n1 Subtype

Grant awards (78)

Vaccine and Treatment Evaluation Unit: Pertussis Vaccine Development$14,174
N01 · FY2021 · AI · contact PI
Vaccine and Treatment Evaluation Unit: Pertussis Vaccine Development$333,763
N01 · FY2017 · AI · contact PI
VTEU: Phase I Influenza Vaccine Clinical Trial$4,825,191
N01 · FY2016 · AI · contact PI
VTEU: Systems Biology Based Assessment of a Pertussis Vaccine$4,055,311
N01 · FY2016 · AI · contact PI
Respiratory Syncytial Virus: Diagnostics Development - VTEU$1,570,670
N01 · FY2015 · AI · contact PI
Vaccine and Treatment Evaluation Units$251,317
N01 · FY2015 · AI · contact PI
Phase I Study of Pandemic Flu Vaccines - VTEU$112,065
N01 · FY2015 · AI · contact PI
Systems Biology Based Assessment of a Pertussis Vaccine - VTEU$66,165
N01 · FY2015 · AI · contact PI
Vaccine and Treatment Evaluation Units$335,005
N01 · FY2014 · AI · contact PI
Vaccine and Treatment Evaluation Units$300,000
N01 · FY2014 · AI · contact PI
Vaccine and Treatment Evaluation Units$96,242
N01 · FY2014 · AI · contact PI
Respiratory Syncytial Virus: Diagnostic and Vaccine Assays - VTEU$57,339
N01 · FY2014 · AI · contact PI
VACCINE AND TREATMENT EVALUATION UNITS$1,721,918
N01 · FY2013 · AI · contact PI
Vaccine and Treatment Evaluation Units$650,000
N01 · FY2013 · AI · contact PI
Vaccine and Treatment Evaluation Units$600,000
N01 · FY2013 · AI · contact PI
VACCINE AND TREATMENT EVALUATION UNITS$600,000
N01 · FY2013 · AI · contact PI
Vaccine and Treatment Evaluation Units$550,000
N01 · FY2013 · AI · contact PI
Vaccine and Treatment Evaluation Units$500,000
N01 · FY2013 · AI · contact PI
Vaccine and Treatment Evaluation Units$300,000
N01 · FY2013 · AI · contact PI
The Incidence and Etiology of Influenza-Associated Community-Acquired Pneumonia i$16,025
U18 · FY2013 · IP · contact PI
VACCINE AND TREATMENT EVALUATION UNITS$500,000
N01 · FY2012 · AI · contact PI
VACCINE AND TREATMENT EVALUATION UNITS$500,000
N01 · FY2012 · AI · contact PI
Vaccine and Treatment Evaluation Units$300,000
N01 · FY2012 · AI · contact PI
The Incidence and Etiology of Influenza-Associated Community-Acquired Pneumonia i$100,000
U18 · FY2012 · IP · contact PI
Vaccine and Treatment Evaluation Units$50,000
N01 · FY2012 · AI · contact PI
VACCINE AND TREATMENT EVALUATION UNITS$1,500,000
N01 · FY2011 · AI · contact PI
VACCINE AND TREATMENT EVALUATION UNITS$1,200,000
N01 · FY2011 · AI · contact PI
The Incidence and Etiology of Influenza-Associated Community-Acquired Pneumonia i$1,093,996
U18 · FY2011 · IP · contact PI
VACCINE AND TREATMENT EVALUATION UNITS$1,018,554
N01 · FY2011 · AI · contact PI
Vaccine and Treatment Evaluation Units$500,000
N01 · FY2011 · AI · contact PI
VACCINE AND TREATMENT EVALUATION UNITS$500,000
N01 · FY2011 · AI · contact PI
VACCINE AND TREATMENT EVALUATION UNITS$500,000
N01 · FY2011 · AI · contact PI
VACCINE AND TREATMENT EVALUATION UNITS$500,000
N01 · FY2011 · AI · contact PI
Vaccine and Treatment Evaluation Units$300,000
N01 · FY2011 · AI · contact PI
The Incidence and Etiology of Influenza-Associated Pneumonia in Hospitalized Pers$995,767
U18 · FY2010 · IP · contact PI
Enhanced Surveillance: New Vaccine Preventable Diseases$497,561
U01 · FY2010 · IP · contact PI
The Incidence and Etiology of Influenza-Associated Pneumonia in Hospitalized Pers$399,818
U18 · FY2010 · IP · contact PI
The Incidence and Etiology of Influenza-Associated Pneumonia in Hospitalized Pers$1,000,000
U18 · FY2009 · IP · contact PI
Vaccine and Treatment Evaluation Units$1,000,000
N01 · FY2009 · AI · contact PI
Enhanced Surveillance: New Vaccine Preventable Diseases$604,248
U01 · FY2009 · IP · contact PI
Enhanced Surveillance: New Vaccine Preventable Diseases$914,792
U01 · FY2008 · IP · contact PI
INF 2205-H5 CHIRON (DMID PROTOCOL 04-062)$12,018
M01 · FY2008 · RR · contact PI
INF 0404-H5 (DMID PROTOCOL 04-076)$5,880
M01 · FY2008 · RR · contact PI
CSL - INF 0506$5,740
M01 · FY2008 · RR · contact PI
CMV FEMALE (DMID 04-039) / CMV MALE (DMID 05-0126)$1,944
M01 · FY2008 · RR · contact PI
BAXTER H5$1,347
M01 · FY2008 · RR · contact PI
INFANT FLU VACCINE STUDY$246
M01 · FY2008 · RR · contact PI
Enhanced Surveillance: New Vaccine Preventable Diseases$785,743
U01 · FY2007 · IP · contact PI
INF 2205-H5 CHIRON (DMID PROTOCOL 04-062)$255,103
M01 · FY2007 · RR · contact PI
INF 0404-H5 (DMID PROTOCOL 04-076)$124,817
M01 · FY2007 · RR · contact PI
NICHD Institutional Training for Pediatricians$123,164
T32 · FY2007 · HD · contact PI
CSL - INF 0506$121,832
M01 · FY2007 · RR · contact PI
CMV FEMALE (DMID 04-039) / CMV MALE (DMID 05-0126)$41,274
M01 · FY2007 · RR · contact PI
BAXTER H5$28,594
M01 · FY2007 · RR · contact PI
INFANT FLU VACCINE STUDY$5,220
M01 · FY2007 · RR · contact PI
Enhanced Surveillance: New Vaccine Preventable Diseases$759,675
U01 · FY2006 · IP · contact PI
INF 1505 - ID/IM (DMID PROTOCOL 050075)$67,536
M01 · FY2006 · RR · contact PI
INF 0404-H5 (DMID PROTOCOL 04-076)$43,626
M01 · FY2006 · RR · contact PI
DMID STX1 STUDY$33,559
M01 · FY2006 · RR · contact PI
ANTHRAX VACCINE STUDY$15,941
M01 · FY2006 · RR · contact PI
INFANT FLU VACCINE STUDY$1,677
M01 · FY2006 · RR · contact PI
EVALUATION OF CONTROL MEASURES AGAINST DISEASES OTHER THAN AIDS-266025-266025462$0
N01 · FY2006 · AI · contact PI
ANTHRAX VACCINE STUDY$245,467
M01 · FY2005 · RR
RESPONSES TO NASAL SPRAY AND SHOT FLU VACCINES$65,857
M01 · FY2005 · RR
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY OF THE SAFETY AND EFFICACY OF$36,382
M01 · FY2005 · RR
CELLULAR IMMUNE RESPONSES IN CHILDREN WITH CONFIRMED INFLUENZA A INFECTION$460
M01 · FY2005 · RR
EXTENSIVE SWELLING REACTIONS AFTER BOOSTER DOSES OF ACELLULAR PERTUSSIS$460
M01 · FY2005 · RR
Enhanced Surveillance: New Vaccine Preventable Diseases$0
U01 · FY2005 · IP
Evaluation of New Bacterial and Viral Candidate Vaccine$413,748
M01 · FY2004 · RR
A Multicenter, Double-Blind, Randomized Study of the Safety and Efficacy of...$128,196
M01 · FY2004 · RR
Responses to Nasal Spray and Shot Flu Vaccines$24,759
M01 · FY2004 · RR
EXTENSIVE SWELLING REACTIONS AFTER BOOSTER DOSES OF ACELLULAR PERTUSSIS$1,101
M01 · FY2004 · RR
Enhanced Surveillance: New Vaccine Preventable Diseases$0
U01 · FY2004 · IP
PLECONARIL (VP63843) THERAPY--INFANTS W/ ENTEROVIRAL MEN$0
M01 · FY2002 · RR
PLECONARIL (VP63843) THERAPY--INFANTS W/ ENTEROVIRAL MEN$0
M01 · FY2001 · RR
PLECONARIL (VP63843) THERAPY--INFANTS W/ ENTEROVIRAL MEN$0
M01 · FY2001 · RR
PLECONARIL (VP63843) THERAPY--INFANTS W/ ENTEROVIRAL MEN$0
M01 · FY2001 · RR
PLECONARIL (VP63843) THERAPY--INFANTS W/ ENTEROVIRAL MEN$0
M01 · FY2000 · RR